AI Terminal
Bastide Le Confort Médical
Interim / Quarterly Report • Mar 19, 2025
1141_iss_2025-03-19_9f050270-41dc-47fe-973c-451c9820225e.pdf
Interim / Quarterly Report
Open in ViewerOpens in native device viewer
2024-2025 half-year results
- Recurring operating margin at 9.1%, up 80 bps
- Operating profit up 10.5% to €22.8 million
- Operating free cash flow largely positive at €9.4 million
- Improvement in financial leverage
2024-2025 outlook: upward revision of recurring operating margin target to 9.1% and a focus on reducing debt
Caissargues, March 19, 2025 – Groupe Bastide, a leading European provider of home healthcare services, published its 2024-2025 half-year results on December 31, 2024. Groupe Bastide's 2024-2025 half-yearly consolidated financial statements have been reviewed by the Group's Statutory Auditors and were approved by its Board of Directors on March 19, 2025. The half-yearly financial report will be published on the Group's website www.bastide-groupe.fr by March 31, 2025, at the latest.
| H1 2023-2024 | H1 2024-2025 | ||
|---|---|---|---|
| In € millions | published* | published | Change |
| Revenue | 264.9 | 275.5 | +4.0% |
| EBITDA | 53.6 | 59.3 | +10.5% |
| EBITDA margin | 20.2% | 21.5% | |
| Recurring operating profit | 21.9 | 25.0 | +14.3% |
| Recurring operating margin | 8.3% | 9.1% | |
| Operating profit | 20.6 | 22.8 | |
| Financial expense | (11.9) | (14.7) | |
| Income tax expense | (5.1) | (5.5) | |
| Net profit from continuing operations | 3.6 | 2.5 | -29.6% |
| Net loss from discontinued operations | (1.2) | (0.4) | |
| Net profit | 2.4 | 2.2 | -8.3% |
| Net profit (loss), Group share | (2.0) | 0.6 |
*Includes five months of Distrimed business (sold in December 2023) and six months of Swiss business (sold in June 2024)
Revenue amounted to €275.5 million (up 4.0% as reported) with organic growth1 of 8.5% in first half 2024-2025, driven by an excellent performance in home healthcare services and a return to growth in Homecare.
With revenue of €175.1 million, the more technical business activities such as Respiratory or Nutrition-Perfusion-Stomatherapy, now represent 64% of the Group's activities. Momentum remains excellent, particularly in the Respiratory and Diabetes businesses, driven by Groupe Bastide's market share gains and structural growth within the sector. On a like-for-like basis, growth in Respiratory care therapy represented 12.1% and 8.5% in Nutrition-Perfusion – Diabetes – Stomatherapy, including 19.2% growth in the Diabetes business.
The "Homecare" business confirms its return to growth, with €100.4 million in revenue in first half 2024-2025, up 5.1%. Local authorities and stores recorded good performance in rental activities, a key area of development for the group. In-store equipment sales also saw a return to growth.
Record recurring operating margin of 9.1%
The gross margin2 rose by 120 basis points over the half-year to reach 68.4%, driven by the strengthening of the home healthcare services and the equipment sales/rental mix.
EBITDA2 amounted to €59.3 million, representing a 10.5% jump, far exceeding the growth in revenue, with a margin of 21.5%, up 130 basis points.
Recurring operating profit2 was up 14.3% over the half-year, amounting to €25.0 million. Recurring operating margin reached a record 9.1%, up 80 basis points compared to first-half 2023-2024.
This performance illustrates the initial positive results of the measures implemented to improve the Group's margins by optimizing both the "Homecare" business and support functions, notably through the pooling of sites, optimization of the store network and tighter payroll control. In the context of development of more technical home healthcare services, the rise in payroll costs was limited to 4.1% over the half-year, and external expenses to 2.2%.
Operating profit increased by 10.5% to €22.8 million. Non-recurring expenses came to €2.2 million, including restructuring costs of €0.7 million, litigation costs of €2.3 million and €1.2 million in capital gains on the recent disposal of the French subsidiary CICA Plus, which specializes in chronic wound care services.
Financial expense came to €14.7 million (vs. €11.9 million in 2023-2024), reflecting the impact of the debt refinancing from July 2024, which extended the maturity of its debt. Financial expenses included
1Organic growth calculated at constant exchange rates and on a like-for-like basis: 2023-2024 figures restated for the contribution of assets sold within the last 12 months and assets classified as held for sale.
2 See definition in appendices.
€1.0 million in interest paid on lease obligations (IFRS 16) and €1.8 million in exceptional non cash financial expenses.
Net profit from continuing operations stood at €2.5 million, after taking into account a €5.5 million tax expense.
Net loss from discontinued operations came in at €0.4 million for the half-year, mainly due to the ongoing disposals in Switzerland.
Therefore, net profit for the period came in at €2.2 million, and net profit, Group share to €0.6 million.
Financial structure: operating free cash flow of €9.4 million
Cash flow from operations came to €53.7 million, including a €4.8 million improvement in working capital requirements thanks to better optimized management of procurement lead times.
It more than offsets net operating investments of €35.1 million over the period. This figure does not reflect the normal level of investments, as it includes the €9 million in one-off investments required to initiate the new contracts won in Canada and the United Kingdom in the Respiratory business, which will only start to contribute to sales at the end of the fiscal year. Excluding this exceptional impact, net capital expenditure remained stable compared to the first half of the previous year.
Operating free cash flow3 (cash flow from operations after net cash flows related to acquisitions of property, plant & equipment and intangible assets and after repayment of lease liabilities), came to a positive €9.4 million, compared to a negative €2.2 million for first-half 2023-2024. Excluding the impact of CapEx related to new contracts won for the Respiratory business, operating free cash flow amounted to €18.4 million, covering all net interest expenses (€16.0 million).
Over the first half of the year, the Group recorded €1.2 million in outflows linked to earn-outs paid on previous years' acquisitions and minority interest buyouts.
Net debt stood at €389.3 million at December 31, 2024 (including €64.8 million in lease liabilities), compared with €385.0 million at June 30, 2024. It includes the €8.0m million cost related to the implementation of the new structured credit in July 2024. Available cash stood at €31.3 million.
Improvement in the Group's financial leverage
In July 2024, Groupe Bastide secured its medium-term financing and extended the maturity of its debt by setting up a new financing contract for €375 million, more than 90% of which being repayable at maturity, as from the 2029-2030 fiscal year.
The new debt is subject to compliance with an IFRS 16/EBITDA net debt3 leverage ratio of 4.5 at December 31, 2024, 4.25 from December 31, 2025 and 4.00 from June 30, 2027. At December 31, 2024, post IFRS 16 leverage stood at 3.48x, well below the authorized threshold of 4.5.
From the fourth quarter of 2024-2025, this performance will enable a reduction in the cost of debt by 25 bps, i.e., an estimated full-year savings of €0.7 million (at constant 3-month Euribor rate).
3 See definition in appendices.
2024-2025 outlook
Structural growth in homecare services, new contracts in the United Kingdom and Canada for the Respiratory business as well as renewed growth in the Homecare business (having recently signed a partnership with the AESIO Santé healthcare group) are all solid drivers of growth.
Thus, despite the 5% price cut in sleep apnea treatment that will take effect from April 1, 2025, Groupe Bastide is reiterating its revenue target of over €560 million (based on its current scope) and raising its target of achieving a recurring operating margin of at least 9.1%, compared with 8.7% previously.
In the second half of 2024-2025, Bastide will carry on with its policy of disciplined management approach for working capital requirement, which, combined with improved profitability and active work on the disposal of targeted assets, will accelerate the Group's debt reduction and improvement of leverage.
NEXT PUBLICATION:
Third-quarter 2024-2025 revenue on Thursday May 15, 2025 after close of trading.
About Groupe Bastide Le Confort Médical
Created in 1977 by Guy Bastide, Groupe Bastide is a leading European provider of home healthcare services. Present in eight countries, Bastide develops a permanent quality approach and is committed to providing medical devices and associated services that best meet patients' needs in key health areas: diabetes, nutrition, infusion, respiratory care, stomatherapy and urology. Bastide is listed on Euronext Paris (ISIN: FR0000035370, Reuters BATD.PA, - Bloomberg BLC: FP).
CONTACTS
| Groupe Bastide | Actus Finance | ||||
|---|---|---|---|---|---|
| Vincent Bastide/Olivier Jourdanney | Analyst-Investor | Press – Media | |||
| T. +33 (0)4 66 38 68 08 | Hélène de Watteville | Déborah Schwartz | |||
| www.bastide-groupe.fr | T. +33 (0)1 53 67 36 33 | T. +33 (0)1 53 67 36 35 |
Alternative performance indicators (reconciliation)
| In € millions | H1 2023-2024 | H1 2024-2025 |
|---|---|---|
| Published revenue | 265.0 | 275.5 |
| Removal from the scope of consolidation of Distrimed since December 2023 |
-5.4 | |
| Removal from the scope of consolidation of the Swiss entities in the process of being sold over the full year (IFRS |
||
| 5) | -4.6 | |
| Store closures | -0.6 | |
| Removal from the scope of consolidation of CICA Plus since | ||
| October 1, 2024 | -0.9 | |
| FX | -0.5 | |
| Restated revenue | 253.5 | |
| Organic growth | +8.5% |
| Gross margin (€ millions) | H1 2023-2024 | H1 2024-2025 |
|---|---|---|
| Revenue | 265.0 | 275.5 |
| - Cost of goods purchased | 87.0 | 87.1 |
| = Gross margin | 178.0 | 188.4 |
| Recurring operating profit (€ millions) | H1 2023-2024 | H1 2024-2025 |
|---|---|---|
| Operating profit | 20.7 | 22.8 |
| + Other non-recurring expenses | 5.0 | 6.8 |
| - Other non-current assets | 3.8 | 4.6 |
| = Recurring operating profit | 21.9 | 25.0 |
| EBITDA (€ millions) | H1 2023-2024 | H1 2024-2025 |
|---|---|---|
| Recurring operating profit | 21.9 | 25.0 |
| + Net depreciation, amortization and provisions | 31.7 | 34.2 |
| = EBITDA | 53.6 | 59.3 |
| Operating free cash flow (€ millions) | H1 2023-2024 | H1 2024-2025 |
|---|---|---|
| Cash flows from operating activities | 34.3 | 53.7 |
| - Cash flows from/(used in) financing activities | 25.7 | 35.0 |
| - Lease liabilities repaid (IFRS 16) | 10.8 | 9.3 |
| = Operating free cash flow | -2.2 | 9.4 |
| Net debt (€ millions) | June 30, 2024 | Dec. 31, 2024 |
|---|---|---|
| Bond issue | 25.4 | 25.4 |
| + Long-term borrowings and loans | 265.6 | 306.0 |
| + Borrowings and short-term bank debt | 47.8 | 24.4 |
| - Cash and cash equivalents | 23.6 | 31.3 |
| = Net debt | 315.2 | 324.5 |
| Net debt (IFRS 16) (€ millions) | June 30, 2024 | Dec. 31, 2024 |
|---|---|---|
| Net debt | 315.2 | 324.5 |
| + Lease liabilities | 69.8 | 64.8 |
| + Deferred payment obligations on shares in subsidiaries | 6.3 | 5.3 |
| = Net debt (IFRS 16) | 391.3 | 394.6 |
Post IFRS 16 leverage =
| Net debt (IFRS 16)/(IFRS 16 EBITDA + normalized contribution from acquisitions) |
June 30, 2024 | Dec. 31, 2024 |
|---|---|---|
| Net debt (IFRS 16) (€ millions) | 391.3 | 394.6 |
| IFRS 16 EBITDA | 107.6 | 113.3 |
| Post IFRS 16 leverage | 3.64 | 3.48 |
Appendices – Balance sheet
| ACTIF (en milliers d'euros) |
Notes | 31/12/2024 | 30/06/2024 |
|---|---|---|---|
| Actifs non courants | 444 204 | 438 145 | |
| Goodwill | 6.1.1 | 208 615 | 208 628 |
| Droits d'utilisation des actifs loués | 6.1.2 | 62 545 | 67 525 |
| Autres actifs incorporels | 6.1.3 | 8 586 | 8 837 |
| Actifs corporels | 6.1.4 | 155 309 | 140 871 |
| Titres mis en équivalence | 6.1.5 | 0 | 88 |
| Autres actifs financiers non courants | 6.1.6 | 8 113 | 9 339 |
| Actifs d'impôts différés | 6.12.2 | 1 036 | 2 858 |
| Actifs courants | 231 763 | 208 922 | |
| Stocks et en cours | 6.2 | 44 784 | 43 207 |
| Clients et comptes rattachés | 6.2 | 82 973 | 78 587 |
| Autres créances | 6.2 | 54 177 | 44 507 |
| Autres actifs courants | 6.2 | 5 671 | 6 229 |
| Trésorerie et équivalents de trésorerie | 6.2.2 | 31 305 | 23 616 |
| Actifs destinés à être cédés | 4.7 | 12 853 | 12 776 |
| TOTAL ACTIF | 675 968 | 647 067 | |
| PASSIF (en milliers d'euros) |
Notes | 31/12/2024 | 30/06/2024 |
| Capital | 3 360 | 3 359 | |
| Primes liées au capital | 9 466 | 9 466 | |
| Résultats accumulés | 63 252 | 66 947 | |
| Capitaux propres attribuables aux propriétaires de la Société | 6.3 | 76 078 | 79 772 |
| Participations ne donnant pas le contrôle | 1 565 | 953 | |
| Total des capitaux propres | 6.3 | 77 643 | 80 725 |
| Passifs non courants | 403 964 | 350 136 | |
| Emprunts obligataires | 6.5.1 | 25 444 | 25 420 |
| Emprunts et dettes financières non courants | 6.5.1 | 323 823 | 265 628 |
| Obligations locatives non courantes | 6.5.5 | 46 019 | 51 679 |
| Provisions non courantes | 6.4 | 1 286 | 1 386 |
| Passif d'impôts différés | 6.12.2 | 2 985 | 1 929 |
Autres passifs non courants 6.6 4 407 4 094 Passifs courants 194 361 216 206 Emprunts et concours bancaires courants 6.5.1 6 581 47 799 Obligations locatives courantes 6.5.5 18 809 18 121 Provisions courantes 6.4 2 329 2 198 Fournisseurs et comptes rattachés 6.6 89 911 77 021 Autres passifs courants 6.6 71 145 65 410 Passifs destinés à être cédés 4.7 5 586 5 657 TOTAL DES CAPITAUX PROPRES ET DES PASSIFS 675 968 647 067
P&L statement
| En milliers d'euros | Notes | 31/12/2024 | 31/12/2023 |
|---|---|---|---|
| Chiffre d'affaires | 6.8.1 | 275 529 | 265 024 |
| Achats consommés | -87 099 | -87 027 | |
| Charges externes | -44 283 | -43 320 | |
| Charges de personnel | -83 643 | -80 374 | |
| Impôts et taxes | -2 143 | -1 888 | |
| Dotations aux amortissements | -33 007 | -31 565 | |
| (Dotations) Reprises aux dépréciations d'actifs et aux provisions | -1 217 | -154 | |
| pour risques et charges Autres produits opérationnels courants |
1 707 | 2 203 | |
| Autres charges opérationnelles courantes | -814 | -1 002 | |
| 25 029 | 21 896 | ||
| Résultat opérationnel courant | |||
| Ajustement de la juste valeur des compléments de prix | 6.9 | 544 | 0 |
| Autres produits opérationnels non courants | 6.9 | 4 015 | 3 794 |
| Autres charges opérationnelles non courantes | 6.9 | -6 766 | -5 041 |
| Résultat opérationnel | 22 823 | 20 649 | |
| Quote-part de résultat net des sociétés mises en équivalence | 6.1.5 | 0 | 0 |
| Résultat opérationnel après quote-part de résultat net dans les | |||
| entités mises en équivalence | 22 823 | 20 649 | |
| Produits de trésorerie et d'équivalents de trésorerie | 0 | 0 | |
| Coût de l'endettement financier brut | -16 426 | -12 947 | |
| Coût de l'endettement financier net | 6.10 | -16 426 | -12 947 |
| Autres produits et charges financiers | 6.11 | 1 673 | 1 021 |
| Résultat avant impôt | 8 069 | 8 723 | |
| Impôt sur le résultat | 6.12 | -5 528 | -5 113 |
| Résultat net des activités poursuivies | 2 541 | 3 610 | |
| Résultat net des activités non poursuivies | -370 | -1 194 | |
| Résultat net | 2 171 | 2 416 | |
| Dont: | |||
| - Part des propriétaires de la Société | 615 | -1 993 | |
| - Part des participations ne donnant pas le contrôle | 1 556 | 4 409 | |
| Résultat net attribuable aux propriétaires de la société mère par action |
|||
| Non dilué (en euros) (*) | 6.14 | 0,08 | -0,27 |
| Dilué (en euros) (**) | 6.14 | 0,08 | -0,25 |
| (*) calculé au titre des différentes périodes sur le nombre d'actions existant : | 7 466 149 | 7 457 499 | |
| (**) calculé au titre des différentes périodes sur le nombre d'actions existant et potentiel : | 7 946 526 | 7 937 876 |
Cash-flow statement
| En milliers d'euros | Notes | 31/12/2024 | 31/12/2023 |
|---|---|---|---|
| Résultat des activités poursuivies | 2 541 | 3 610 | |
| Résultat des activités non maintenues | -370 | -1 194 | |
| Dotations nettes aux amortissements et provisions | 6.1 | 22 377 | 21 269 |
| Dotations aux amortissements des droits d'utilisation des actifs loué (IFRS 16) | 6.1.2 | 10 630 | 10 347 |
| Gains et pertes latents liés aux variations de juste valeur | 2 | -4 | |
| Charges et produits calculés aux stocks-options et assimilés | 0 | 0 | |
| Autres produits et charges calculés | -576 | 0 | |
| Plus et moins-values de cession | -1 169 | -2 681 | |
| Profits et pertes de dilution | 0 | 0 | |
| Quote-part de résultat liés aux sociétés mises en équivalence | 0 | 0 | |
| Dividendes sur entités non consolidés | 0 | -42 | |
| Impact des activités abandonnées | 4.7 | 0 | 0 |
| Capacité d'autofinancement après coût de l'endettement financier net et impôt | 33 436 | 31 305 | |
| Coût de l'endettement financier net | 6.10 | 16 426 | 12 555 |
| Charge d'impôt (y compris impôts différés) | 6.12.1 | 5 528 | 5 113 |
| Capacité d'autofinancement avant coût de l'endettement financier net et impôt | 55 390 | 48 973 | |
| Impôt versé | -6 434 | -5 781 | |
| Variation du BFR lié à l'activité | 6.7 | 4 763 | -10 434 |
| Autres flux liés aux activités opérationnelles | 0 | 0 | |
| Impact des activités abandonnées | 0 | 1 512 | |
| Flux de trésorerie liés aux activités opérationnelles | 53 719 | 34 270 | |
| Incidence des variations de périmètre | -1 242 | 12 741 | |
| Acquisition d'immobilisations corporelles et incorporelles | 6.1 | -37 611 | -25 960 |
| Cession d'immobilisations corporelles et incorporelles | 2 568 | 289 | |
| Acquisition d'actifs financiers | 0 | -719 | |
| Cession d'actifs financiers | 0 | 473 | |
| Variation des prêts et avances consentis | -61 | -493 | |
| Dividendes reçus sur titres non consolidés | 0 | 42 | |
| Autres flux liés aux opérations d'investissement | 0 | 0 | |
| Impact des activités abandonnées | 0 | 0 | |
| Flux de trésorerie liés aux activités d'investissement | -36 347 | -13 626 | |
| Versement des actionnaires de la société mère lors d'augmentation de capital | 0 | 0 | |
| Versement des minoritaires lors d'augmentation de capital | 0 | 0 | |
| Cession (acquisition) nette d'actions propres | 0 | -3 | |
| Dividendes versés | -1 100 | -1 996 | |
| Emission d'emprunts | 6.5.1 | 326 461 | 41 695 |
| Remboursement d'emprunts | 6.5.1 | -310 168 | -34 758 |
| Remboursement des obligations locatives ( IFRS 16) | 6.5.5 | -9 341 | -10 830 |
| Intérêts financiers nets versés | -15 971 | -12 555 | |
| Autres flux liés aux opérations de financement | 0 | -3 087 | |
| Impact des activités abandonnées | 0 | 0 | |
| Flux de trésorerie liés aux activités de financement | -10 119 | -21 534 | |
| Incidence des variations des cours des devises | 231 | -51 | |
| Variation de la trésorerie nette | 7 484 | -941 | |
| Trésorerie d'ouverture | 23 612 | 36 707 | |
| Trésorerie de clôture | 31 096 | 35 766 | |
| Trésorerie et équivalents de trésorerie | 6.2.2 | 31 305 | 35 766 |
| Trésorerie passive | 6.2.2 | -209 | 0 |
